Mar, 2023 - By CMI
The growing number of beta-thalassemia patients worldwide is expected to fuel market expansion during the forecast period. Leading market participants are concentrating on filing applications for drug therapy approval for the treatment of beta-thalassemia, which is projected to fuel development in the worldwide beta-thalassemia (B-thal) market over the forecast period. Throughout the projection period, the worldwide beta-thalassemia (B-thal) market is predicted to develop due to a robust product pipeline for the treatment of beta-thalassemia. Strict pricing and reimbursement rules, as well as the high cost of medications used in the treatment of beta-thalassemia, are projected to stymie growth in the worldwide beta-thalassemia market throughout the forecast period.
According to Coherent Market Insights, the global Beta-thalassemia (B-thal) Market is estimated to be valued at US$ 411.8 million in 2021 and is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028).
Key Companies in the Beta-thalassemia (B-thal) Industry:
1. Celgene Corp.
Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.the company was founded in 1986, headquartered in New Jersey, U.S. -Bristol-Myers Squibb Company announced that it has completed its acquisition of Celgene Corporation following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019
2. CRISPR Therapeutics
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. CRISPR Therapeutics HostED Innovation Day on June 21, 2022, Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics.
3. Kiadis Pharma
Founded in 1997, Kiadis is committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands. On 2 November 2020 Sanofi and Kiadis Pharma N.V. announced that they have entered into a definitive merger agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares of Kiadis at a price per Kiadis share of €5.45 in cash
4. Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
5. Editas Medicine
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine And Shoreline Biosciences Enter Into Definitive Agreement For Shoreline To Acquire Editas’ INK Cell Franchise And Related Gene Editing Technologies on January 19, 2023
6. Global Blood Therapeutics
On August 2022, Pfizer Inc. and Global Blood Therapeutics, Inc. (GBT) announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, headquartered in California, U.S.
7. Syros Pharmaceuticals
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. On September 2022, Syros Pharmaceuticals, Inc. announced the closing of its merger with Tyme Technologies, Inc., pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million.
8. Sangamo Therapeutics, Inc
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
*Definition- Beta thalassemia is a hereditary blood condition in which the patient's body cannot produce enough haemoglobin. Clinically, beta-thalassemia patients can be divided into two groups based on their requirement for blood transfusions: transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT).